BioNTech Announces Second Quarter Financial Results and Corporate Update
Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well...
Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well...
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with...
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
A widespread outbreak of monkeypox will be yet another stressor on the nursing professionSilver Spring, MD, Aug. 05, 2022 (GLOBE...
RTHM collaborating on Tollovid™ 3CL inhibitor immune support supplement case studiesTollovid biomarker data to support potential structure-function claims in Long...
Record Quarterly Building Supply Segment Sales of $10.8 Million, Up 10.4% Net sales for the second quarter of 2022 were...
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA...
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first...
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarterCONSHOHOCKEN, Pa.,...
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold...
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions,...
Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse eventsFLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE...
Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg.Pharmacokinetics (PK) were dose...
SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics,...
SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments...
Larger order for 2023 follows initial order for supply in 2022 COPENHAGEN, Denmark, August 3, 2022 – Bavarian Nordic A/S...
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Data shows how Medicare Advantage company’s efforts in 2021 improved member health; outlines environmental, social and governance approach Alignment Healthcare...
Company to host conference call to discuss financial results and provide a corporate update on August 9, 2022 at 4:30...